Outsourcing Facilities That Still Produce GLP-1s in 2026: The Current Roster

The landscape for 503B outsourcing facilities producing compounded GLP-1 medications has contracted dramatically since 2024. With semaglutide and tirzepatide both removed from the FDA drug shortage list and the 503B Bulks List exclusion proposed, the legal pathway for large-scale GLP-1 compounding by outsourcing facilities has effectively closed. But "effectively" is not "entirely" — and understanding who is still operating, under what authority, and for how long matters for patients and providers navigating this market.

The Regulatory Backdrop

503B outsourcing facilities operate under Section 503B of the FDCA, which allows them to compound medications at scale without individual patient prescriptions — but only from ingredients on the 503B Bulks List or for drugs currently on the FDA drug shortage list. As of mid-2026:

• Semaglutide: Off the drug shortage list since February 2025. Not on the 503B Bulks List. Proposed for permanent exclusion from the Bulks List (April 2026 proposal, comment period closed June 29, 2026).
• Tirzepatide: Off the drug shortage list since October 2024. Not on the 503B Bulks List. Also proposed for permanent Bulks List exclusion.
• Liraglutide: Not currently in shortage. Also proposed for Bulks List exclusion.

This means 503B outsourcing facilities have no current legal basis to compound GLP-1 medications from bulk API. Any 503B facility still producing compounded semaglutide or tirzepatide in mid-2026 is operating in a regulatory gray zone — either working through existing inventory compounded during the shortage period, compounding under a different legal theory, or operating in non-compliance.

Who Is Still Operating — and How

Facilities With Pre-Shortage Inventory

Some outsourcing facilities compounded large quantities of GLP-1 preparations while the drugs were on the shortage list. Products compounded during the shortage period and within their beyond-use dating remain legal to dispense until they expire. This "inventory drawdown" approach is finite — once existing stock is depleted, production cannot legally resume without a change in regulatory status.

Facilities Pursuing Legal Challenges

The Outsourcing Facilities Association and individual 503B facilities have pursued multiple legal challenges against the FDA's shortage-list removal decisions and enforcement actions. While federal courts have consistently denied motions for preliminary injunctions, some facilities continue to operate while litigation proceeds — betting that a favorable ruling could retroactively validate their continued production.

This is a high-risk strategy. Courts have not been sympathetic to compounders' arguments, and operating without legal authorization during litigation increases the facility's exposure to enforcement action.

Facilities That Transitioned to 503A

Some former outsourcing facilities have restructured their operations to function under 503A authority — switching from batch production to patient-specific compounding. This requires fundamental operational changes: individual prescriptions for each patient, a bona fide prescriber-patient-pharmacy relationship, and compliance with 503A's different regulatory framework. Facilities that successfully make this transition can continue compounding GLP-1s, but at lower volume and with different economic dynamics.

Why 503A Is Now the Dominant Pathway

The vast majority of compounded GLP-1 prescriptions in mid-2026 flow through 503A pharmacies — traditional compounding pharmacies that prepare patient-specific prescriptions. This shift happened because:

• 503A authority does not depend on the drug shortage list or the Bulks List
• 503A pharmacies can compound from commercially available bulk drug substances (API from FDA-registered suppliers) under state pharmacy law
• The telehealth prescribing model naturally generates patient-specific prescriptions that satisfy 503A's requirements
• Most telehealth GLP-1 platforms pivoted to 503A pharmacy partnerships well before the shortage-list removals

For patients, the practical consequence is that the source of their compounded GLP-1 has likely shifted from a large-scale outsourcing facility to a smaller, patient-specific compounding pharmacy — even if the telehealth platform they use hasn't changed.

What Happens When the Bulks List Decision Becomes Final

If the FDA finalizes the permanent exclusion of semaglutide, tirzepatide, and liraglutide from the 503B Bulks List (expected 2027), it will formalize what is already the practical reality: 503B outsourcing facilities cannot produce compounded GLP-1s. The finalization will eliminate any remaining legal ambiguity and likely trigger a final wave of facility closures and transitions.

For 503A pharmacies and their patients, the Bulks List decision changes nothing directly — 503A operates under different statutory authority. But the political and regulatory attention surrounding the decision may lead to additional scrutiny of all compounding pathways, including 503A.

Providers With Durable 503A Pharmacy Partnerships